Effects of selective and non-selective cyclo-oxygenase inhibition on endothelial function in patients with rheumatoid arthritis

Scandinavian Journal of Rheumatology

Volumn 36, Issue 4, 2007, Pages 265-269

  Wong, M ^a   Jiang, B Y ^b   McNeill, K ^b   Farish, S ^c   Kirkham, B ^a   Chowienczyk, P ^b,d  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLYCERYL TRINITRATE; GOLD; HYDROXYCHLOROQUINE; INDOMETACIN; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; SALAZOSULFAPYRIDINE;

ADULT; AORTA; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL FUNCTION; BRACHIAL ARTERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE MARKER; DOUBLE BLIND PROCEDURE; DYSPEPSIA; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; ENZYME INHIBITION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; HYPEREMIA; INFLAMMATION; MALE; PRIORITY JOURNAL; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VASODILATATION;

AGE OF ONSET; ARTHRITIS, RHEUMATOID; BODY MASS INDEX; CYCLOOXYGENASE 2 INHIBITORS; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; HEALTH STATUS; HUMANS; INDOMETHACIN; INFLAMMATION; LACTONES; MALE; MIDDLE AGED; PLACEBOS; QUESTIONNAIRES; SULFONES;

EID: 34548336819     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740701286771     Document Type: Article

References (17)

1. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population-based nested case-control analysis. Br Med J 2005;330:1366.
2. Wong M, Chowienczyk P, Kirkham B. Cardiovascular issues of COX-2 inhibitors and NSAIDs. Aust Fam Physician 2005;34:945-8.
3. Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 2002;46:862-73.
4. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001;104:2673-8.
5. Wong M, Toh L, Wilson A, Rowley K, Karschimkus C, Prior D, et al. Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation. Arthritis Rheum 2003;48:81-9.
6. Chenevard R, Hurlimann D, Bechir M, Enseleit F, Spieker L, Hermann M, et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003;107:405-9.
7. Taddei S, Virdis A, Ghiadoni L, Salvetti A. Vascular effects of endothelin-1 in essential hypertension: relationship with cyclooxygenase-derived endothelium-dependent contracting factors and nitric oxide. J Cardiovasc Pharmacol 2000;35:S37-40.
8. Widlansky ME, Price DT, Gokce N, Eberhardt RT, Duffy SJ, Holbrook M, et al. Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension 2003;42:310-15.
9. Verma S, Raj SR, Shewchuk L, Mather KJ, Anderson TJ. Cyclooxygenase-2 blockade does not impair endothelial vasodilator function in healthy volunteers: randomized evaluation of rofecoxib versus naproxen on endothelium-dependent vasodilatation. Circulation 2001;104:2879-82.
10. Title LM, Giddens K, McInerney MM, McQueen MJ, Nassar BA. Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. J Am Coll Cardiol 2003;42:1747-53.
11. Bogaty P, Brophy JM, Noel M, Boyer L, Simard S, Bertrand F, et al. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study. Circulation 2004;110:934-9.
12. Tikiz C, Utuk O, Bayturan O, Bayindir P, Ekmekci C, Tikiz H. Selective COX-2 inhibition with different doses of rofecoxib does not impair endothelial function in patients with coronary artery disease. Acta Med Okayama 2005;59:11-17.
13. Curtis SP, Ng J, Yu Q, Shingo S, Bergman G, McCormick CL, et al. Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials. Clin Ther 2004;26:70-83.
14. Brune K, Hinz B. Selective cyclooxygenase-2 inhibitors: similarities and differences. Scand J Rheumatol 2004;33:1-6.
15. Hermann M, Camici G, Fratton A, Hurlimann D, Tanner FC, Hellermann JP, et al. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Circulation 2003;108:2308-11.
16. Niederberger E, Manderscheid C, Grosch S, Schmidt H, Ehnert C, Geisslinger G. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. Biochem Pharmacol 2004;68:341-50.
17. Koki A, Khan NK, Woerner BM, Dannenberg AJ, Olson L, Seibert K, et al. Cyclooxygenase-2 in human pathological disease. Adv Exp Med Biol 2002;507:177-84.